Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 May 2025 | Story André Damons | Photo Supplied
Dr Lisa Rothmann
Dr Lisa Rothmann, a plant disease epidemiologist from the University of the Free State (UFS), has been nominated in the TW Kambule-NSTF Award: Emerging Researcher category for this year’s NSTF-South32 Awards.

Dr Lisa Rothmann, a plant disease epidemiologist from the University of the Free State (UFS) who was nominated in the TW Kambule-NSTF Award: Emerging Researcher category for this year’s NSTF-South32 Awards, says that the nomination is a reminder that service through science matters.

“I am humbled by the nomination. For me, it reflects not just individual recognition, but also the shared effort of the team of postgraduate academics, research assistants, partners, and farmers with whom I've had the privilege to work with. It is affirming to see plant pathology and field-based research recognised in this way; it highlights the consistent (hard) work we do to make a meaningful contribution to agriculture and to serve the grain industry and farmers,” says Dr Rothmann. 

She was nominated by Grain South Africa (Grain SA), with whom she has been working closely since 2018 to contribute research that aligns with the organisation’s mission to strengthen the grain sector. They play a key role in supporting sustainable grain production and farmer development. 

Dr Rothmann, who is one of eight UFS researchers and a research team nominated for the NSTF-South32 Awards – also known as the ‘Science Oscars’ – is nominated for her contribution to interdisciplinary, team-based research to develop practical solutions for plant diseases in order to protect crops and empower communities. 

 

Motivation to keep growing

The Senior Lecturer in the Department of Plant Sciences within the Faculty of Natural and Agricultural Sciences (NAS) says that while she is proud of the work she has done, she sees this recognition as a team effort. Says Dr Rothmann: “It motivates me to keep growing as a researcher, rooted in impact and integrity. I’m not a prolific peer-reviewed publisher; my academic record includes 10 journal articles and one book chapter, but I have written around 50 popular articles – often as a solo author, in collaboration with postgraduates and peers.” 

“These pieces translate plant pathology topics such as the Sclerotinia life cycle, disease surveillance, and management into accessible information for producers and the public. To me, this nomination is a symbol that making a meaningful impact doesn't only come from journal impact factors. This nomination has reminded me that building a career in academia is a relay, not a race, and that lasting impact comes from investing in others.”

As a plant disease epidemiologist, she specialises in field pathology – an area of plant pathology that explores how disease epidemics in crops develop, spread, and can be effectively managed within agricultural systems. Their work centres on understanding and managing Sclerotinia diseases in oilseed and protein crops such as canola, soybean, and sunflower, as well as disease surveillance in key grain crops including dry bean, sorghum, and sunflower.

 

New research

After participating in the US-based National Sclerotinia Initiative in 2017, she was inspired to establish a South African Sclerotinia Research Network with the support of Grain SA, creating a platform for researcher collaboration, farmer engagement, and the development of on-farm management strategies. Over time, explains Dr Rothmann, their research has expanded to include cultivar screening, national disease surveys, fungicide registration trials, and the development of disease-assessment tools. More recently, they have embedded sociological surveys into sorghum disease work to better understand farmers’ knowledge and needs, ensuring that research remains practical and co-created with producers.

According to Dr Rothmann, they have been privileged to work in a space that supports producers and protects crops through applied plant disease management strategies. While high-value crops often attract attention due to export markets, the grain that feed the nation forms the backbone of food security. As part of their new research, Dr Rothman and the research team are currently contributing to the Sorghum Cluster Initiative's pre-breeding programme, where they have screened 160 accessions for diseases to support future cultivar development. 

They are also going to explore how both emerging and commercial farmers will adopt these new cultivars. She is actively seeking collaborators in sociology/psychology or similar fields to better understand farmers’ decision-making. They are developing a plant disease dashboard to map disease occurrences across South Africa – an effort aligned with the Plant Health (Phytosanitary) Act 35 of 2024 to help guide appropriate disease risk categorisation. In the long term, concludes Dr Rothmann, they hope to establish a diagnostic hub for central South Africa in partnership with Agricultural Research Council-Grain Crops to strengthen local disease identification and support producers in real time.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept